Jefferies Starts MediWound Ltd (MDWD) at Buy

Jefferies initiates coverage on MediWound Ltd (NASDAQ: MDWD) with a Buy rating and a price target of $19.00.

Analyst Raj Denhoy comments, "MediWound’s NexoBrid is a novel and potentially disruptive technology in the treatment of severe burns. By reducing the time, cost, and morbidity associated with the treatment of these injuries, MediWound’s novel debridement agent has the promise of becoming the standard of care for hundreds of thousands of patients a year."

For an analyst ratings summary and ratings history on MediWound Ltd click here. For more ratings news on MediWound Ltd click here.

Shares of MediWound Ltd closed at $11.71 yesterday.

You May Also Be Interested In

• MediWound to Report Second Quarter 2026 Financial Results
• Oil States International (OIS) PT Lowered to $14 at Stifel
• Sony (SONY) PT Raised to $23 at Bernstein SocGen Group